Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Antengene Corporation Limited ( (HK:6996) ) is now available.
Antengene Corporation Limited has announced that its board of directors will convene on March 20, 2026, to review and approve the annual results of the company and its subsidiaries for the financial year ended December 31, 2025. The meeting will also address the publication of these results, a key disclosure event for investors and other stakeholders monitoring the company’s financial performance and governance.
The board currently comprises Chairman and executive director Dr. Jay Mei, executive director Mr. Donald A. Lung, and independent non-executive directors Ms. Jing Qian, Mr. Sheng Tang, and Dr. Rafael Fonseca. The composition underscores the company’s adherence to Hong Kong listing governance requirements, and the upcoming results announcement is likely to provide further insight into Antengene’s operational progress and strategic positioning over the past year.
The most recent analyst rating on (HK:6996) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 6996. The company focuses on the discovery, development, and commercialization of innovative therapies, operating through a group structure that includes multiple subsidiaries.
YTD Price Performance: 3.17%
Average Trading Volume: 2,772,955
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.48B
Find detailed analytics on 6996 stock on TipRanks’ Stock Analysis page.